颗粒酶B PET显像评估心肌梗死炎症与重塑
本研究在大鼠心肌梗死模型中评价68Ga-grazytracer靶向颗粒酶B的PET/CT显像能否刻画心脏炎症与重塑。心肌梗死后第3天摄取最高(0.294±0.03%ID/g vs 假手术组0.122±0.01%ID/g,P<0.001),GzmB抑制剂治疗组摄取显著低于MI组(0.184±0.03%ID/g vs 0.286±0.03%ID/g,P<0.001)。作者认为该显像有潜力描绘不良炎症反应和病理性心脏重塑,并有助于预测心功能。
要点
- 大鼠MI后第3天68Ga-grazytracer摄取最高,为0.294±0.03%ID/g,假手术组为0.122±0.01%ID/g(P<0.001)。
- GzmB抑制剂治疗组摄取0.184±0.03%ID/g,显著低于MI组0.286±0.03%ID/g(P<0.001)。
- GzmB抑制剂治疗可改善心功能,但未显著缩小梗死面积。
核心结论
- 68Ga-grazytracer显像有潜力描绘不良炎症反应和病理性心脏重塑,有助于预测心功能。
- PET/CT显像引导的治疗可能减轻心肌损伤并改善MI后心功能。
研究设计与样本
- 大鼠心肌梗死模型,于术后第1、3、6、14、28天行GzmB靶向PET/CT。
- 体外行放射自显影、Masson染色、免疫组化和ELISA验证炎症反应与重塑。
- 用GzmB抑制剂Z-IETD-FMK治疗大鼠以改善心脏重塑,MI后6周行超声心动图检查心功能。
主要发现
- MI后第3天68Ga-grazytracer摄取最高,为0.294±0.03%ID/g,假手术组为0.122±0.01%ID/g(P<0.001)。
- 免疫组化显示GzmB和CD8高表达,与PET/CT显像结果一致。
- 放射自显影显示68Ga-grazytracer在梗死心肌中聚集。
- 治疗组大鼠68Ga-grazytracer摄取为0.184±0.03%ID/g,显著低于MI组的0.286±0.03%ID/g(P<0.001)。
- 超声心动图显示MI组左心室射血分数低于缺血再灌注组;GzmB抑制剂治疗有效改善心功能,但未显著缩短梗死面积。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate whether granzyme B (GzmB)-targeted positron emission tomography (PET) imaging agent (68 Ga-grazytracer) can characterize cardiac inflammation and remodeling in myocardial infarction (MI). METHODS: Rats with MI were subjected to GzmB-targeted PET/CT on post-operative days 1, 3, 6, 14, and 28. Autoradiography, Masson staining, immunohistochemistry, and ELISA were performed to verify the inflammatory response and remodeling after MI in vitro. Rats were treated with GzmB inhibitor Z-IETD-FMK to improve cardiac remodeling. Cardiac function tests were performed by echocardiography at 6 weeks after MI. RESULTS: The highest uptake of 68 Ga-grazytracer was observed on day 3 after MI compared with the values obtained on the other days (0.294 ± 0.03% ID/g at 3 days vs. 0.122 ± 0.01% ID/g in the sham group, P < 0.001). Immunohistochemistry showed significantly high expression of GzmB and CD8, in line with the PET/CT imaging results. Autoradiography revealed 68 Ga-grazytracer accumulation in the infarcted myocardium. The 68 Ga-grazytracer uptake of treated rats was significantly reduced compared with that in the MI groups (0.184 ± 0.03%ID/g vs. 0.286 ± 0.03%ID/g; P < 0.001). Echocardiography showed that the left ventricular ejection fraction was lower in the MI groups than in the ischemia reperfusion group. GzmB inhibitor treatment was shown to be effective in improving cardiac function without significantly shortening infarct size. CONCLUSIONS: This study demonstrated the potential of 68 Ga-grazytracer imaging to delineate adverse inflammatory responses and pathological cardiac remodeling, which can help predict heart function. PET/CT imaging-guided therapy may reduce myocardial injury and improve heart function in MI.
引用
- Xu H, Wei Z, Chen B, et al. Granzyme B PET imaging inflammation and remodeling in myocardial infarction. Eur J Nucl Med Mol Imaging. 2023. PMID: 37991527. doi:10.1007/s00259-023-06521-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。